Volume 3, Issue 3 (2017)                   Pharm Biomed Res 2017, 3(3): 17-22 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Azimzadeh K, Jafarpour H, Adldoost S. Sertraline alters level of adenosine deaminase activity, oxidative stress markers and cardiac biomarkers (homocysteine cardiac troponin I) in rats. Pharm Biomed Res. 2017; 3 (3) :17-22
URL: http://pbr.mazums.ac.ir/article-1-174-en.html
1- Young Researcher and Elite Club, Urmia Branch, Islamic Azad University, Urmia, Iran
2- Student of Veterinary Medicine, Veterinary faculty, Urmia Branch, Islamic Azad University, Urmia, Iran
Abstract:   (2745 Views)
The aim of this study is whether oxidative stress markers, homocysteine (Hcy), cardiac troponin I (cTnI) and the activity of adenosine deaminase (ADA) alter following administration of different doses of sertraline. Sixty male Wistar rats were assigned into four groups. Sertraline at doses of 20, 40 and 80 mg / kg / day) were administered to three groups through gastric gavage for 90 days. The fourth group was received only distilled water. After 90 days of sertaline administration, the levels of oxidative stress biomarkers in plasma were measured. The results revealed remarkable elevation in malondialdehyde (MDA) and considerable reduction in Hcy, cTnI, antioxidant enzymes levels as superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and paraoxonase (PON)and ADA activity in the rats that were receive sertraline at dose of 80 mg /Kg /day. The results denoted that sertraline administration at the dose of 80 mg/kg/day reduce cardiovascular biomarkers. Meanwhile, decrease of ADA activity may suggest reduction of immune function due to sertraline administration.
Full-Text [PDF 1089 kb]   (1816 Downloads)    
Type of Study: Original Research | Subject: Pharmacology

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb